Shanghai Shyndec Pharmaceutical Co Ltd (600420) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shanghai Shyndec Pharmaceutical Co Ltd (600420) has a cash flow conversion efficiency ratio of 0.031x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥486.04 Million ≈ $71.12 Million USD) by net assets (CN¥15.70 Billion ≈ $2.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shanghai Shyndec Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Shanghai Shyndec Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Shanghai Shyndec Pharmaceutical Co Ltd (600420) financial obligations for a breakdown of total debt and financial obligations.
Shanghai Shyndec Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shanghai Shyndec Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chin Hin Group Bhd
KLSE:5273
|
-0.029x |
|
Ls Cable & System Asia Ltd
KO:229640
|
-0.008x |
|
Bank of Zhengzhou Co Ltd Class A
SHE:002936
|
-0.076x |
|
TIANQI LITHIUM H YC 1
F:2220
|
N/A |
|
Galapagos NV ADR
NASDAQ:GLPG
|
-0.013x |
|
Dno ASA
OL:DNO
|
0.444x |
|
Diamondrock Hospitality Company Common Stock
NYSE:DRH
|
0.047x |
|
Topoint Technology Co Ltd
TW:8021
|
0.023x |
Annual Cash Flow Conversion Efficiency for Shanghai Shyndec Pharmaceutical Co Ltd (2004–2025)
The table below shows the annual cash flow conversion efficiency of Shanghai Shyndec Pharmaceutical Co Ltd from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Shanghai Shyndec Pharmaceutical Co Ltd worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥34.93 Billion ≈ $5.11 Billion |
CN¥1.70 Billion ≈ $248.48 Million |
0.049x | -66.98% |
| 2024-12-31 | CN¥15.32 Billion ≈ $2.24 Billion |
CN¥2.26 Billion ≈ $330.12 Million |
0.147x | +22.71% |
| 2023-12-31 | CN¥14.34 Billion ≈ $2.10 Billion |
CN¥1.72 Billion ≈ $251.74 Million |
0.120x | -48.94% |
| 2022-12-31 | CN¥12.15 Billion ≈ $1.78 Billion |
CN¥2.86 Billion ≈ $417.87 Million |
0.235x | +45.07% |
| 2021-12-31 | CN¥10.37 Billion ≈ $1.52 Billion |
CN¥1.68 Billion ≈ $245.79 Million |
0.162x | +1.94% |
| 2020-12-31 | CN¥9.82 Billion ≈ $1.44 Billion |
CN¥1.56 Billion ≈ $228.30 Million |
0.159x | +15.13% |
| 2019-12-31 | CN¥9.20 Billion ≈ $1.35 Billion |
CN¥1.27 Billion ≈ $185.86 Million |
0.138x | -30.19% |
| 2018-12-31 | CN¥8.44 Billion ≈ $1.24 Billion |
CN¥1.67 Billion ≈ $244.25 Million |
0.198x | -34.68% |
| 2017-12-31 | CN¥7.65 Billion ≈ $1.12 Billion |
CN¥2.31 Billion ≈ $338.69 Million |
0.303x | +150.41% |
| 2016-12-31 | CN¥6.94 Billion ≈ $1.02 Billion |
CN¥838.58 Million ≈ $122.71 Million |
0.121x | -14.06% |
| 2015-12-31 | CN¥1.61 Billion ≈ $235.83 Million |
CN¥226.65 Million ≈ $33.17 Million |
0.141x | -24.27% |
| 2014-12-31 | CN¥1.39 Billion ≈ $203.72 Million |
CN¥258.51 Million ≈ $37.83 Million |
0.186x | +18.60% |
| 2013-12-31 | CN¥1.33 Billion ≈ $193.92 Million |
CN¥207.50 Million ≈ $30.36 Million |
0.157x | -3.62% |
| 2012-12-31 | CN¥1.19 Billion ≈ $174.21 Million |
CN¥193.41 Million ≈ $28.30 Million |
0.162x | +13.10% |
| 2011-12-31 | CN¥947.63 Million ≈ $138.67 Million |
CN¥136.12 Million ≈ $19.92 Million |
0.144x | +4.53% |
| 2010-12-31 | CN¥837.59 Million ≈ $122.57 Million |
CN¥115.11 Million ≈ $16.84 Million |
0.137x | +0.63% |
| 2009-12-31 | CN¥713.46 Million ≈ $104.40 Million |
CN¥97.43 Million ≈ $14.26 Million |
0.137x | +48.57% |
| 2008-12-31 | CN¥631.47 Million ≈ $92.40 Million |
CN¥58.04 Million ≈ $8.49 Million |
0.092x | -33.63% |
| 2007-12-31 | CN¥594.29 Million ≈ $86.96 Million |
CN¥82.31 Million ≈ $12.04 Million |
0.138x | -3.74% |
| 2006-12-31 | CN¥511.49 Million ≈ $74.85 Million |
CN¥73.60 Million ≈ $10.77 Million |
0.144x | +19.00% |
| 2005-12-31 | CN¥478.84 Million ≈ $70.07 Million |
CN¥57.90 Million ≈ $8.47 Million |
0.121x | +213.99% |
| 2004-12-31 | CN¥441.88 Million ≈ $64.66 Million |
CN¥17.02 Million ≈ $2.49 Million |
0.039x | -- |
About Shanghai Shyndec Pharmaceutical Co Ltd
Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company offers 6-APA, potassium clavulanate series, diclofenac sodium extended release tablets, urine-derived biochemical products, nifedipine controlled release tablets, azithromycin, ceftriaxone sodium for injection, methylprednisolone sodium succinate… Read more